Mea Car-T细胞疗法治疗市场规模及2031年预测

MEA CAR-T 细胞治疗市场分析和规模

MEA 地区癌症发病率的上升是 Car-T 细胞治疗市场的主要驱动力，因此对更有效的治疗的需求也日益增长。然而，Car-T 细胞治疗的高成本构成了重大障碍，可能会限制其普及。从好的方面来看，该地区越来越重视医疗基础设施建设和医疗旅游，尤其是在新加坡等国家，这为市场带来了增长机会。然而，一个重大挑战是需要进行广泛的研究和临床试验，以确定 Car-T 细胞治疗在该地区长期的疗效和安全性。

Data Bridge Market Research分析，MEA CAR-T细胞疗法治疗市场预计到2031年将达到1.0569亿美元，在2027年至2031年的预测期内以30.7%的复合年增长率增长。

报告指标	细节
预测期	2027 至 2031 年
基准年	2023
历史岁月	2022（可定制为 2016 – 2021）
定量单位	收入（百万美元）
涵盖的领域	产品（自体 CAR-T 细胞和同种异体 CAR-T 细胞）、结构（第一代 CAR-T 细胞、第二代 CAR-T 细胞、第三代 CAR-T 细胞和第四代 CAR-T 细胞）、靶向抗原（实体肿瘤抗原、血液系统恶性肿瘤抗原等）、品牌（Yescarta、Kymriah、Tecartus 等）、治疗应用（弥漫性大 B 细胞淋巴瘤、滤泡性淋巴瘤、急性淋巴细胞白血病 (ALL)、套细胞淋巴瘤、多发性骨髓瘤、血液系统恶性肿瘤、肺癌、慢性淋巴细胞白血病、胃癌、胰腺癌、乳腺癌等）、最终用户（医院、专科诊所等）、分销渠道（医院药房等）
覆盖国家	沙特阿拉伯、南非、阿联酋、以色列、科威特、埃及以及中东和非洲其他地区
涵盖的市场参与者	诺华公司、吉利德科学公司、百时美施贵宝公司、强生服务公司等

市场定义

CAR-T 细胞疗法或嵌合抗原受体 T 细胞是经过基因改造的 T 细胞，可产生人工 T 细胞受体，用于免疫治疗各种癌症。嵌合抗原受体是实验室改造的受体蛋白，可为 T 细胞提供靶向特定蛋白质的新能力。这些受体是嵌合的，因为它们结合抗原结合和 T 细胞激活功能，形成单一受体。一旦 CAR-T 细胞注入患者体内，它们就会充当“活细胞”，具有杀死有害癌细胞而不影响健康细胞的能力或设计。当 CAR-T 细胞与细胞上的靶向抗原接触时，CAR-T 细胞会与其结合并被激活和繁殖，从而产生细胞毒性。

MEA CAR-T 细胞疗法治疗市场动态

本节旨在了解市场驱动因素、机遇、限制因素和挑战。下文将详细讨论所有这些内容：

驱动程序

癌症和其他目标疾病的发病率不断上升

癌症是全球发病和死亡的主要原因，由于人口增长、老龄化和生活方式改变等因素，这些地区的癌症发病率正在上升。此外，其他目标疾病（如血液病）的负担也越来越重，这些疾病也可以通过 CAR-T 细胞疗法治疗。这种不断增加的疾病负担凸显了对创新和有效治疗方法（如 CAR-T 细胞疗法）的需求，从而推动了市场增长。

人们对 Car-T 细胞疗法的认识和接受度不断提高

在 MEA、沙特阿拉伯和 MEA 地区，人们越来越意识到并接受 CAR-T 细胞疗法是一种有效的治疗方法，这得益于多种因素。这些因素包括媒体报道的增加、医疗机构的教育工作以及分享强调该疗法有效性的成功案例。因此，患者和医疗服务提供者对 CAR-T 细胞疗法的潜在优势有了更好的了解，例如更高的反应率和持久的缓解，尤其是在难治性或复发病例中。此外，这些地区的监管部门的批准和认可巩固了 CAR-T 细胞疗法作为一种合法且可行的治疗选择的地位。

机会

Car-T 细胞疗法的广泛研发管线

广泛的产品线为患者、医疗保健提供者和整个医疗保健行业带来了大量机会。该产品线包括一系列处于不同开发阶段的 CAR-T 细胞疗法产品，从早期临床前研究到高级临床试验。该产品线反映了 CAR-T 细胞疗法的持续创新和投资，正在开发的新产品针对不同类型的癌症和血液病。此外，该产品线还包括旨在提高 CAR-T 细胞疗法的安全性、有效性和可及性的产品，例如下一代 CAR-T 细胞疗法和现成的 CAR-T 细胞产品。

约束/挑战

Car-T细胞疗法成本高昂

CAR-T 细胞疗法是一种高度个性化且复杂的治疗方法，涉及修改患者的免疫细胞以靶向癌细胞，因此该过程成本高昂。造成这种高成本的因素包括专门的制造过程、广泛的临床监测和基础设施要求。因此，许多患者，尤其是那些没有足够保险或财务资源的患者，在获得这种创新疗法方面面临挑战。临床试验、法规遵从性和治疗后监测的成本进一步增加了总体费用，凸显了患者的经济负担，尤其是来自低收入家庭的患者。

治疗的潜在风险和不良反应

尽管 CAR-T 细胞疗法具有良好的疗效，但它也存在潜在的风险和副作用，对 MEA、沙特阿拉伯和 MEA 地区的患者和医疗保健提供者构成了挑战。最常见的副作用包括细胞因子释放综合征 (CRS) 和神经毒性。当注入的 CAR T 细胞识别并攻击癌细胞时，就会发生 CRS，这是一种严重的不良反应，会导致释放细胞因子，如白细胞介素 6 (IL-6)。这种免疫反应会引起全身炎症，表现为轻度发烧和流感样症状，以及可能危及生命的并发症，如低血压、呼吸窘迫和多器官衰竭。CAR T 细胞疗法还可引发免疫效应细胞相关神经毒性综合征 (ICANS)，其特征是神经系统症状，如意识模糊、癫痫发作和言语障碍。这些副作用是由免疫系统过度激活和细胞因子释放引起的，强调需要密切监测和及时管理，以确保患者安全和治疗效果。

最新动态

2023 年 12 月，吉利德科学公司宣布，美国 FDA 已批准 Yescarta（axicabtagene ciloleucel）的标签更新，以纳入具有里程碑意义的 3 期 ZUMA-7 研究的总生存期 (OS) 主要分析，该分析表明，对于在完成一线治疗后 12 个月内复发或难治性大 B 细胞淋巴瘤 (R/R LBCL) 患者的二线治疗中，Yescarta 在 OS 方面与标准治疗 (SOC) 相比具有统计学上的显着改善
2022 年 5 月，百时美施贵宝公司宣布日本厚生劳动省批准 Opdivo 和 Yervoy 作为成人患者的一线治疗方案。这可能有助于该公司加强其产品组合
2022 年 2 月，FDA 批准了杨森的 CARVYKTI™ (ciltacabtagene autoleucel)，用于治疗已接受过四种或更多种疗法治疗的复发或难治性多发性骨髓瘤成人患者，这是杨森的首个细胞疗法。这将凸显其致力于推进肿瘤治疗方案的决心
2021 年 12 月，诺华公司与百济神州有限公司签署了一项关于 ociperlimab (BGB-A1217) 的协议，增强了该公司的免疫肿瘤学研发。此次合作有助于诺华肿瘤学部门通过将一种具有潜在变革性的疗法纳入其不断扩展的免疫治疗平台，推动癌症治疗创新的更广泛计划

MEA CAR-T 细胞疗法治疗市场范围

MEA CAR-T 细胞疗法治疗市场根据产品、结构、靶向抗原、品牌、治疗应用、最终用户和分销渠道分为七个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。

产品

自体CAR-T细胞
同种异体 CAR-T 细胞

根据产品，市场分为自体 CAR-T 细胞和同种异体 CAR-T 细胞。

结构

第一代 CAR-T 细胞
第二代CAR-T细胞
第三代CAR-T细胞
第四代CAR-T细胞

根据结构，市场分为第一代 CAR-T 细胞、第二代 CAR-T 细胞、第三代 CAR-T 细胞和第四代 CAR-T 细胞。

靶向抗原

实体肿瘤抗原
血液系统恶性肿瘤抗原
其他的

根据目标抗原，市场分为实体肿瘤抗原、血液系统恶性肿瘤抗原和其他抗原。

品牌

耶斯卡塔
基姆里亚
特卡图斯
其他的

根据品牌，市场细分为 yescarta、kymriah、tecartus 和其他。

治疗应用

血液系统恶性肿瘤
胰腺癌
乳腺癌
肺癌
胃癌
多发性骨髓瘤
慢性淋巴细胞白血病
套细胞淋巴瘤
滤泡性淋巴瘤
弥漫性大 B 细胞淋巴瘤
急性淋巴细胞白血病 (ALL)
其他的

根据治疗应用，市场细分为弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤、急性淋巴细胞白血病 (ALL)、套细胞淋巴瘤、多发性骨髓瘤、血液系统恶性肿瘤、肺癌、慢性淋巴细胞白血病、胃癌、胰腺癌、乳腺癌等。

最终用户

医院
专科诊所
其他的

根据最终用户，市场分为医院、专科诊所和其他。

分销渠道

医院药房
其他的

根据分销渠道，市场分为医院药房和其他。

MEA CAR-T 细胞治疗市场区域分析/见解

MEA CAR-T 细胞疗法治疗市场根据产品、结构、靶向抗原、品牌、治疗应用、最终用户和分销渠道分为七个显著的部分。

本市场报告涵盖的国家包括沙特阿拉伯、南非、阿联酋、以色列、科威特、埃及以及中东和非洲的其他国家。

沙特阿拉伯凭借其先进的医疗基础设施、政府支持、不断发展的医疗旅游业、研发活动以及对先进治疗的不断增长的需求，有望主导 MEA CAR-T 细胞疗法治疗市场。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了区域品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战以及销售渠道的影响。

竞争格局和 MEA CAR-T 细胞治疗市场份额分析

MEA CAR-T 细胞疗法治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品批准、产品宽度和广度、应用主导地位以及产品类型生命线曲线。以上提供的数据点仅与公司对市场的关注有关。

该市场的一些主要市场参与者包括诺华公司、吉利德科学公司、百时美施贵宝公司和强生服务公司等。

SKU-61531

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

表格列表

TABLE 1 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 TOTAL STATISTICS OF PREVELENCE RATE OF CANCER -2022(KENYA)

TABLE 3 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 4 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 5 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE, 2022-2031 (USD MILLION)

TABLE 6 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE, 2022-2031 (USD MILLION)

TABLE 7 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGET ANTIGEN, 2022-2031 (USD MILLION)

TABLE 8 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGET ANTIGEN, 2022-2031 (USD MILLION)

TABLE 9 SEA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 10 MEA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 11 SEA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 12 MEA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 13 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 14 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 15 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTICS APPLICATION, 2022-2031 (USD MILLION)

TABLE 16 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTICS APPLICATION, 2022-2031 (USD MILLION)

TABLE 17 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 18 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 19 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 20 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 22 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 23 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 24 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 25 SAUDI ARABIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 26 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 27 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 28 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 29 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 30 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 31 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 32 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 33 U.A.E. ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 34 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 35 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 36 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 37 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 38 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 39 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 40 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 41 SOUTH AFRICA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 42 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 43 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 44 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 45 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 46 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 47 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 48 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 49 ISRAEL ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 50 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 51 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 52 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 53 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 54 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 55 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 56 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 57 KUWAIT ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 58 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 59 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 60 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 61 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 62 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 63 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 64 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 65 EGYPT ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 66 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 67 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 68 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 69 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 70 REST OF MIDDLE EAST & AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 71 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 72 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 73 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 74 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 75 SINGAPORE ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 76 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 77 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 78 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 79 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 80 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 81 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 82 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 83 MALAYSIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 84 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 85 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 86 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 87 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 88 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 89 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 90 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 91 THAILAND ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 92 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 93 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 94 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 95 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 96 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 97 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 98 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 99 INDONESIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 100 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 101 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 102 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 103 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 104 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 105 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 106 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 107 PHILIPPINES ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 108 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 109 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 110 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 111 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 112 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 113 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 114 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 115 VIETNAM ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 116 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 117 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 118 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 119 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

图片列表

FIGURE 1 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: SEGMENTATION

FIGURE 2 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: MULTIVARIATE MODELLING

FIGURE 8 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 10 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: SEGMENTATION

FIGURE 12 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT IS EXPECTED TO DRIVE THE MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL DIALYSIS MACHINES AND CONSUMABLES MARKET

FIGURE 14 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2031

FIGURE 15 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, CAGR (2024-2031)

FIGURE 16 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 17 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2031

FIGURE 18 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, CAGR (2027-2031)

FIGURE 19 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 20 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2031

FIGURE 21 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, CAGR (2024-2031)

FIGURE 22 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, LIFELINE CURVE

FIGURE 23 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2031

FIGURE 24 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, CAGR (2027-2031)

FIGURE 25 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, LIFELINE CURVE

FIGURE 26 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, 2031

FIGURE 27 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, CAGR (2024-2031)

FIGURE 28 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, LIFELINE CURVE

FIGURE 29 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, 2031

FIGURE 30 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY TARGET ANTIGEN, CAGR (2027-2031)

FIGURE 31 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY TARGET ANTIGEN, LIFELINE CURVE

FIGURE 32 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2031

FIGURE 33 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, CAGR (2024-2031)

FIGURE 34 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, LIFELINE CURVE

FIGURE 35 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2031

FIGURE 36 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY BRAND, CAGR (2027-2031)

FIGURE 37 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY BRAND, LIFELINE CURVE

FIGURE 38 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, 2031

FIGURE 39 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, CAGR (2024-2031)

FIGURE 40 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, LIFELINE CURVE

FIGURE 41 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, 2031

FIGURE 42 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY THERAPEUTICS APPLICATION, CAGR (2027-2031)

FIGURE 43 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY THERAPEUTICS APPLICATION, LIFELINE CURVE

FIGURE 44 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, 2031

FIGURE 45 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, CAGR (2024-2031)

FIGURE 46 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, LIFELINE CURVE

FIGURE 47 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, 2031

FIGURE 48 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, CAGR (2027-2031)

FIGURE 49 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, LIFELINE CURVE

FIGURE 50 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2031

FIGURE 51 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 52 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 53 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2031

FIGURE 54 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2027-2031)

FIGURE 55 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 56 MEA, CAR-T CELL THERAPY MARKET: SNAPSHOT (2023)

FIGURE 57 SEA, CAR-T CELL THERAPY MARKET: SNAPSHOT (2023)

FIGURE 58 MEA CAR-T CELL THERAPY MARKET: COMPANY SHARE 2023 (%)

FIGURE 59 SEA CAR-T CELL THERAPY MARKET: COMPANY SHARE 2023 (%)

查看详细信息

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

How big is the MEA CAR-T Cell Therapy Treatment Market?

The MEA CAR-T Cell Therapy Treatment Market size will be worth USD 105.69 million by 2031.

What is the growth rate of the MEA CAR-T Cell Therapy Treatment Market?

The MEA CAR-T Cell Therapy Treatment Market growth rate will be 30.7% by 2031.

What are the growth drivers of the MEA CAR-T Cell Therapy Treatment Market?

The Increasing Prevalence of Cancer and other Target Diseases, Growing Awareness and Acceptance of Car-T Cell Therapy are the growth drivers of the MEA CAR-T Cell Therapy Treatment Marke

What are the factors on which the MEA CAR-T Cell Therapy Treatment Market research is based on?

The product, structure, targeted antigens, brand, therapeutic application, end user and distribution channel are the factors on which the MEA CAR-T Cell Therapy Treatment Market research is based.

Which are the major companies in the MEA CAR-T Cell Therapy Treatment Market?

The major companies in the MEA CAR-T Cell Therapy Treatment Market are Novartis AG, Gilead Sciences, Inc., Bristol-Myers Squibb Company, and Johnson & Johnson Services, Inc. etc

MEA CAR-T 细胞治疗市场 – 行业趋势和 2031 年预测

MEA CAR-T 细胞治疗市场 – 行业趋势和 2031 年预测

MEA CAR-T 细胞治疗市场分析和规模

MEA CAR-T 细胞疗法治疗市场动态

MEA CAR-T 细胞疗法治疗市场范围

MEA CAR-T 细胞治疗市场区域分析/见解

竞争格局和 MEA CAR-T 细胞治疗市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

报告

市场洞察

支持

解决方案

MEA CAR-T 细胞治疗市场 – 行业趋势和 2031 年预测

MEA CAR-T 细胞治疗市场 – 行业趋势和 2031 年预测

MEA CAR-T 细胞治疗市场分析和规模

MEA CAR-T 细胞疗法治疗市场动态

MEA CAR-T 细胞疗法治疗市场范围

MEA CAR-T 细胞治疗市场区域分析/见解

竞争格局和 MEA CAR-T 细胞治疗市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

浏览相关页面